Cancer mortality data consistently favor people in the US versus their UK counterparts for a variety of reasons.

Quality of Life as an outcome in cancer clinical trials is an often overlooked but key aspect of the outcome of new cancer treatments.

Germline testing for inherited genetic variants is recommended to many people with cancer, yet such useful testing is notably underutilized.

Education about cancer clinical trials can increase trial enrollment by improving impressions, reducing fears, and raising awareness.

Choosing NGS first rather than Single-Gene Testing in cancer is a financially effective and diagnostically efficient strategy in many cases.

To enroll in clinical trials for targeted cancer therapies, people must be aware of them; thus, raising awareness is vital to enrollment.

Liquid biopsy for cancer is non-invasive and easily repeated, permitting molecular profiling and many other purposes with strong accuracy.

We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.

We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.

Awareness of new and emerging cancer biomarkers and compounds is vital so HCPs will test for and treat molecular oncogenic drivers.

NGS is useful for diagnosis and prognosis but also for treatment decisions and resistance monitoring yet it is not consistently used.